An increasing number of technologies combine spatial discrimination with molecule identification, as has been done for decades through immunohistochemistry and in situ hybridization. The difference is that now a range of commercially available platforms promises to significantly increase the number of targets that can be identified on a single sample. These platforms also provide higher throughput in terms of the number of samples that can be interrogated, and some offer semi-automation with straightforward sample preparation.
These characteristics promise to make the new spatial profiling technologies attractive candidates for biomedical research facilities, but in order to discriminate between them, it is necessary to share real-world experiences using them in core labs.
This session will share the experience at New York University Langone Health using Nanostring’s GeoMx digital spatial profiling platform as a service for research laboratories. Dr. Valeria Mezzano of NYU Langone will discuss how her team approaches each project, interacts with clinical researchers, and performs the assays as an integrated network of core facilities.